CEA Investissement et al. back Bioaxial

CEA backed the company via its Amorcage Technologique Investissement fund, an early-stage vehicle that typically invests €200,000-600,000 in funding rounds worth up to €2m for technology-focused start-ups.

The capital injection will allow Bioaxial to begin its pursuit of commercialisation; the company plans on marketing its products to the life sciences industry within the next 12 months. The commercial launch of Bioaxial's first product is expected to take place in the first half of next year.

Company
Founded in 2010, Bioaxial is headquartered in Paris and currently employs five staff. The company has developed a range of fluorescence microscopy instruments, designed to enable greater imaging and provide "super-resolution" of live cells.

Bioaxial's optical modules are designed to work as add-on modules on commercial microscopes. The company also develops stand-alone instruments. Its optical microscopy module, which is due for commercial launch next year, has been tested at the Institut Pasteur for the past 12 months.

People
CEO Gabriel Sirat and CTO Louis-Philippe Braitbart are the founders of Bioaxial. Celia Hart is an investment director at CEA Investissement, while Matthieu Coutet is a managing director at ITI. Jerome Feraud is an investment director at Viveris.

Advisers
Equity – Chammas & Marcheteaux, Lola Chammas (Legal).
Company – King & Wood Mallesons SJ Berwin, Pierre Louis Perin (Legal); Innovatys Consulting, Anne-Helene Nicolas (Corporate finance); Arenatis, Alain Rodermann (Corporate finance).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• France
• Early-stage
• Healthcare
• France
• CEA Investissement